Capricor Therapeutics Inc  

(Public, NASDAQ:CAPR)   Watch this stock  
Find more results for Deborah G Smith
3.70
+0.09 (2.49%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.55 - 3.76
52 week 1.88 - 5.40
Open 3.62
Vol / Avg. 62,612.00/43,673.00
Mkt cap 64.85M
P/E     -
Div/yield     -
EPS -0.84
Shares 17.95M
Beta -1.69
Inst. own 4%
Aug 11, 2016
Q2 2016 Capricor Therapeutics Inc Earnings Release (Estimated) Add to calendar
Jun 22, 2016
Capricor Therapeutics Inc at ROTH Healthcare Day
May 12, 2016
Q1 2016 Capricor Therapeutics Inc Earnings Call
May 12, 2016
Q1 2016 Capricor Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -351.11% -233.02%
Operating margin -346.54% -228.57%
EBITD margin - -226.56%
Return on average assets -103.54% -86.58%
Return on average equity - -
Employees 29 -
CDP Score - -

Address

2ND FLOOR, 8840 WILSHIRE BLVD
BEVERLY HILLS, CA 90211
United States - Map
+1-310-3583200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Officers and directors

Frank I. Litvack M.D. Independent Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Linda Marban Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Leland J. Gershell M.D. Ph.D. Chief Financial Officer, Principal Financial Officer
Age: 44
Bio & Compensation  - Reuters
Karen G. Krasney J.D. Executive Vice President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Anthony Bergmann Principal Accounting Officer, Vice President - Finance
Age: 29
Bio & Compensation  - Reuters
Thomas Lyle Copmann Ph.D. Vice President - Regulatory Affairs and Drug Development
Age: 61
Bio & Compensation  - Reuters
Houman Hemmati M.D., Ph.D. Vice President - Medical & Clinical Development, New Therapies
Bio & Compensation  - Reuters
Luis Rodriguez-Borlado Ph.D. Vice President - Regenerative Therapies
Bio & Compensation  - Reuters
Rachel Smith Ph.D. Vice President - Research & Development
Age: 36
Bio & Compensation  - Reuters
Deborah Ascheim M.D. Chief Medical Officer
Bio & Compensation  - Reuters